Vol 8, Supp. C (2017)
Case report
Published online: 2017-12-31

open access

Page views 357
Article views/downloads 707
Get Citation

Connect on Social Media

Connect on Social Media

Effectiveness of ruxolitinib in the treatment of patients with myelofibrosis with co-morbidities

Katarzyna Kotwica-Mojzych, Iwona Hus, Barbara Jodłowska-Jędrych, Mariusz Mojzych, Marek Hus

Abstract

Myelofibrosis (MF) is a heterogenous Philadelphia-myeloproliferative neoplasm that is characterized by bone marrow fibrosis and impaired hematopoiesis. Clinical hallmarks of MF are increased splenomegaly, cytopenias and general symptoms. Deregulation of JAK–STAT signaling pathway plays a key role in the pathogenesis of MF. Ruxolitinib is a selective and oral JAK1/JAK2 inhibitor that in clinical trials demonstrated significant efficacy in the reduction of clinical symptoms, improved the quality of life and increased overall survival of patients with MF.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs. 2012; 17(4): 555–570.
  2. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17): 3842–3847.
  3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.
  4. Erf LA, Herbut PA. Primary and secondary myelofibrosis (a clinical and pathological study of thirteen cases of fibrosis of the bone marrow). Ann Intern. 1944; 21(5): 863–889.
  5. Alshemmari SH, Rajan R, Emadi A. Molecular pathogenesis and clinical significance of driver mutations in primary myelofibrosis: a review. Med Princ Pract. 2016; 25(6): 501–509.
  6. Mui AL. The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci. 1999; 55(12): 1547–1558.
  7. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012; 119(14): 3219–3225.
  8. Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011; 118(25): 6515–6520.
  9. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013; 37(2): 214–220.
  10. Čokić VP, Mitrović-Ajtić O, Beleslin-Čokić BB, et al. Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in myeloproliferative neoplasms. Mediators Inflamm. 2015; 2015: 453020.
  11. Alchalby H, Lioznov M, Fritzsche-Friedland U, et al. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant. 2012; 47(1): 143–145.
  12. Verstovsek S, Mesa RA, Gotlib J, et al. COMFORT-I investigators. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med. 2013; 125(1): 128–135.
  13. Burger R, Bugdahn T, Staudinger M, et al. Preclinical activity of the JAK1/2 inhibitor ruxolitinib on malignant plasma cell growth and survival. J Clin Oncol. 2014; 20(2): e18565.
  14. Harrison CN, Kiladjian JJ, Gisslinger H, et al. Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study. Blood. 2011; 118: 279.
  15. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787–798.
  16. Verstovsek S, Mesa RA, Gotlib J. The results of COMFORT-I, a double-blind placebo-controlled Phase III study of ruxolitinib demonstrated the significant benefit of ruxolitinib in reducing spleen size, alleviating symptoms and improving quality of life in patients with MF. N Engl J Med. 2012; 366: 799–807.
  17. Verstovsek S, Mesa RA, Gotlib J, et al. COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1): 55.
  18. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010; 16(3): 358–367.
  19. Sacha T. Skuteczność leczenia pierwotnej mielofibrozy inhibitorami kinazy JAK2. Hematologia. 2013; 3: 197–205.
  20. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787–798.
  21. Wróbel T. Ruksolitynib w leczeniu nowotworów mieloproliferacyjnych Ph(-). Acta Haematol Pol. 2015; 46(4): 292–298.
  22. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–1707.
  23. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047–4053.
  24. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015; 100(9): 1139–1145.



Hematology in Clinical Practice